Find a Doctor

Return to Physician Search

Physician Profile


David M. Waterhouse, M.D., MPH

Clinical research is a particular area of interest for Dr. Waterhouse, co-chair of OHC’s Research Department and a principal investigator. “I am passionate about clinical research and its benefits for our patients.” Compassionate care is another goal of Dr. Waterhouse, having been inspired by “an oncologist who introduced me to a very different side of cancer care.”
Learn More.


Medical Oncology


Blue Ash


or call


Lung cancer
Urologic cancer
Clinical trials research


Cancer research and its impact on patients.


Reading, ice hockey, and dog shows.


University of Massachusetts Medical School


University of Massachusetts Medical Center


University of Massachusetts Medical Center


University of Michigan


University of Michigan School of Public Health, M.P.H.


American Board of Internal Medicine, Internal Medicine
American Board of Internal Medicine, Medical Oncology
American Board of Internal Medicine, Hematology


Academy of Medicine, Cincinnati
Alpha Sigma Nu
American Cancer Society
American Society of Clinical Oncology
Ohio State Medical Society
Ohio/West Virginia Hematology Oncology Society


Chair, OHC Clinical Research Department
Clinical Research Committee, American Society of Clinical Oncology
Professional Advisory Committee, Cincinnati Relationship Center
Professional Advisory Committee, Hospice of Cincinnati
Board of Medical Advisors, Cancer Support Community


Top Doctor, Medical Oncology, Cincinnati Magazine, 2013-2010, 2007-2008, 1998
Top Doctor, Hematology, Cincinnati Magazine, 2013-2010, 2007-2008, 2003
Unsung Hero Award, Cancer Family Care, 2008
Clinical Trials Participation Award, American Society of Clinical Oncology, 2007
Young Investigator Award, American Society of Clinical Oncology, 1992
Fellow, American Cancer Society, 1989
Summa cum laude and Alpha Sigma Nu, Holy Cross, 1981

Waterhouse D.; "Clinical Trials Should be a First Step in Cancer Treatment, Not the Last." Published online, ohcare.com, Aug. 26, 2013.

Yardley D, Hart L, Waterhouse DM, Whorf R, Drosick DR, Murphy P, Badarinath S, Daniel BR, Childs BH, Burris HA 3rd. Addition of Bevacizumab to Three Docetaxel Regimens as Adjuvant Therapy for Early-Stage breast Cancer. Breast Cancer Res Treat.  Accepted for Publication 2013

Spigel DR, Waterhouse DM, Lane S, Legenne P, Bhatt K. Efficacy and Safety of Oral Topotecan and Bevacizumab Combination as Second-Line Treatment for Relapsed Small-Cell Lung Cancer: An Open-Label, Multicenter, Single-Arm, Phase II Study. Clinical Lung Cancer. Clin Lung Cancer. 2013 Jul; 14(4):356-63

Hainsworth JD, Shipley DL, Reeves J Jr, Arrowsmith ER, Barnes EK, Waterhouse DM.  High-Dose Bevicizumab in the Treatment of Patients with Advanced Clear Cell Renal Carcinoma: A Phase II Trial of the Sarah Cannon Oncology Research Consortium. Clin Genitourin Cancer. 2013 May 14

Hainsworth JD, Waterhouse DM, Penley WC, Shipley DL, Thompson DS, Webb CD, Anthony Grecco F. Sorafenib and Everolimus in Advanced Clear Cell Renal Carcinoma: A Phase I/II Trial of the SCRI Oncology Research Consortium. Cancer Invest. 2013 Jun; 31(5):323-9. Epub 2013 Apr 24

Infante JR, Arkenau HT, Bendell JC, Rubin MS, Waterhouse D, Jones GT, Spiegel DR, Lane CM, Hainsworth JD, Burris HA 3rd.. Lenalidomide in Combination with Gemcitabine as First-Line Treatment for Patients with Metastatic Carcinoma of the Pancreas. Cancer Biol Ther. Apr; 14(4):340-6. Epub 2013 Jan 28

Yardley DA, Hart L, Bosserman L, Salleh MN,Waterhouse DM, Hagan MK, Richards P, DeSailvio ML, Mahoney JM, Nagarwala Y. Phase II Study Evaluating Lapatanib in Combination with Nab-Paclitaxel in Her2-Overexpressing Metastatic Breast Cancer Patients Who Have Received No More Than One Prior Chemotherapeutic Regimen. Breast Cancer Res Treat. 2013 Jan; 137(2):457-64. Epub 2012 Dec 8

Spigel DR, Anthony Grecco F, Waterhouse DM, Shipley DL, Zubkus JD, Bury MJ, Webb CD, Hart LL, Gian VG, Infante JR, Burris HA 3rd, Hainsworth JD. Phase II Trial of Ixabepilone and Carboplatin with or without Bevacizumab in Patients with Previously Untreated Advanced Non-Small-Cell Lung Cancer. Lung Cancer. 2012 Oct; 78(1):70-75. Epub 2012 Sep 1

Bendell JC, Meluch A, Peyton J, Rubin M, Waterhouse D, Webb C, Burris HA 3rd, Hainsworth JD. A Phase II Trial of Preoperative Concurrent Chemotherapy/Radiation Therapy plus Bevacizumab/Erlotinib in the Treatment of Localized Esophageal Cancer. Clin Adv Hematol Oncol. 2012 Jul; 10(7):430-437

Madajewicz S, Waterhouse DM, Ritch PS, Khan MQ, Higby DJ, Leichman CG, Malik SK, Hentschel P, Gill JF, Zhao L, Nichol SJ. Multicenter, Randomized Phase II Study of Bevacizumab Plus Folinic Acid, Fluoruracil, Gemcitabine (FFG) versus Bevacizumab Plus Folinic Acid, Fluoruracil, Oxaliplatin (FOLFOX4) as First-Line Therapy for Patients with Advanced Colorectal Cancer. Invest New Drugs. 2012 Apr; 30(2):772-778. Epub 2010 Dec 1

Jackson K, Guinigundo A, Waterhouse D: Bone Marrow Aspiration and Biopsy: A Guideline for Procedural Training and Competency Assessment. J Adv Prct Oncology. 2012; 3: 260-265

Baselga J, Cortes J, Kim SB, Im SA, Hegg R, Im YH, Roman L, Pedrini JL, Pirnkowowski T, Knott A, Clark E, Benyunes MC, Ross G, Swain SM: CLEOPATRA Study Group. N Engl J Med. 2012 Jan 12; 366(2):109-19. Epub 2011 Dec 7

Spigel DR, Hainsworth JD, Shipley DL, Ervin TJ, Kohler PC, Lubiner ET, Peyton JD, Waterhouse DM, Burris HA 3rd, Grecco FA: A Randomized Phase II Trial of Pemetrexed/Gemcitabine//Bevacizumab or Pemetrexed/Carboplatin/Bevacizumab in the First-Line Treatment of Elderly Patients with Advanced Non-Small-Cell Lung Cancer.  J Thoracic Oncol. 2011 Jan; 7(1):196-202

Spigel D, Burris H, Grecco A, Shipley D, Friedman E, Waterhouse D, Whorf R, Mitchell B, Daniel D, Zangmeister J, Bass J, Hainsworth J: Randomized Double-Blind Placebo-Controlled Phase II Trial of Sorafenib and Erotinib or Erotinib Alone in Previously Treated Advanced Non-Small-Cell Lung Cancer. J Clin Oncology. 2011 June 20: 2582-2589

For a complete list, contact Dr. Waterhouse at 1-800-710-4674.

Dr. Waterhouse is a principal investigator and co-chief of the Clinical Trial Research Department at OHC. Like all OHC physicians, he has full access to the OHC clinical trial research program.

We encourage our patients to discuss all of their healthcare options — including Clinical Trial research programs — with their doctor.

The following are recent reviews provided by actual OHC patients:

"Dr. Waterhouse has always shown strong interest in me and my concerns. His communications regarding my problem have always been excellent and his decisions as to care, tests, treatment have been exactly what has been needed. I have total confidence in him."

"Dr. Waterhouse is a great, caring and incredible doctor. I have perfect belief, and trust in his capabilities and expertise as a doctor. There is a heartfelt interest that he shows that is extremely rare and comforting. We are all extremely lucky to have a doctor of his caliber in the Cincinnati Community. In all honesty I believe he worked just as hard to beat my Cancer as I did!!!"

"I am thrilled to have Dr. Waterhouse as my oncologist."